These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

88 related articles for article (PubMed ID: 22239510)

  • 21. Telaprevir can be successfully and safely used to treat older patients with genotype 1b chronic hepatitis C.
    Furusyo N; Ogawa E; Nakamuta M; Kajiwara E; Nomura H; Dohmen K; Takahashi K; Satoh T; Azuma K; Kawano A; Tanabe Y; Kotoh K; Shimoda S; Hayashi J;
    J Hepatol; 2013 Aug; 59(2):205-12. PubMed ID: 23542346
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Utility of week-4 viral response to tailor treatment duration in hepatitis C virus genotype 3/HIV co-infected patients.
    Crespo M; Esteban JI; Ribera E; Falco V; Sauleda S; Buti M; Esteban R; Guardia J; Ocaña I; Pahissa A
    AIDS; 2007 Feb; 21(4):477-81. PubMed ID: 17301566
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Do steatosis and steatohepatitis impact on sustained virological response (SVR) rates in patients receiving pegylated interferon and ribavirin for chronic hepatitis C infection?
    Cross TJ; Quaglia A; Nolan J; Hughes S; Harrison PM
    J Med Virol; 2010 May; 82(6):958-64. PubMed ID: 20419809
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Effect of prolonged administration of pegylated interferon/ribavirin therapy in genotypes 2a and 2b: propensity score-matched analysis.
    Yokoyama S; Kawakami Y; Imamura M; Hayes CN; Kohno H; Kohno H; Tsuji K; Aisaka Y; Kira S; Yamashina K; Nonaka M; Takahashi S; Moriya T; Kitamoto M; Aimitsu S; Nakanishi T; Kawakami H; Chayama K
    J Gastroenterol Hepatol; 2015 Feb; 30(2):337-44. PubMed ID: 25091289
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Boceprevir plus peginterferon α-2b/ribavirin in chronic hepatitis C genotype 1: impact of baseline viral load on sustained virologic response.
    Gordon SC; Reddy KR; Jacobson IM; Poordad F; Bronowicki JP; Bacon B; Buti M; Hu KQ; Pedicone LD; Burroughs M; Brass CA; Albrecht JK; Lawitz EJ
    J Clin Gastroenterol; 2014; 48(5):435-43. PubMed ID: 24177376
    [TBL] [Abstract][Full Text] [Related]  

  • 26. New proposal for response-guided peg-interferon-plus-ribavirin combination therapy for chronic hepatitis C virus genotype 2 infection.
    Abe H; Aida Y; Ishiguro H; Yoshizawa K; Seki N; Miyazaki T; Itagaki M; Sutoh S; Ika M; Kato K; Shimada N; Tsubota A; Aizawa Y
    J Med Virol; 2013 Sep; 85(9):1523-33. PubMed ID: 23775277
    [TBL] [Abstract][Full Text] [Related]  

  • 27. [Efficacy of pegylated interferon alpha-2a and ribavirin treatment in chronic hepatitis C patients depends on various baseline parameters and early viral kinetics].
    Husa P; Slesinger P; Stroblová H; Svobodník A; Husová L
    Klin Mikrobiol Infekc Lek; 2008 Apr; 14(2):67-73. PubMed ID: 18756436
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Peginterferon alfa-2a plus ribavirin is more effective than peginterferon alfa-2b plus ribavirin for treating chronic hepatitis C virus infection.
    Ascione A; De Luca M; Tartaglione MT; Lampasi F; Di Costanzo GG; Lanza AG; Picciotto FP; Marino-Marsilia G; Fontanella L; Leandro G
    Gastroenterology; 2010 Jan; 138(1):116-22. PubMed ID: 19852964
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Therapy of chronic hepatitis C with PEG-IFN α-2b plus ribavirin in patients with genotype 2 or 3: 16 versus 24 weeks, clinical outcome and direct cost analyses.
    Fabris P; Carlotto A; Del Bianco T; Malfatti F; Tramarin A; Miotti MA; Baldo V; Floreani A; Giordani MT; Grasso A
    Eur J Gastroenterol Hepatol; 2013 Dec; 25(12):1396-401. PubMed ID: 23743559
    [TBL] [Abstract][Full Text] [Related]  

  • 30. The use of different Peg-interferon alpha-2b regimens plus ribavirin in HCV-1b-infected patients after rapid virological response does not affect the achievement of sustained virological response.
    Napoli N; Giannelli G; Antonaci A; Antonaci S
    J Viral Hepat; 2008 Apr; 15(4):300-4. PubMed ID: 18307592
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Peginterferon alfa-2b and ribavirin: effective in patients with hepatitis C who failed interferon alfa/ribavirin therapy.
    Poynard T; Colombo M; Bruix J; Schiff E; Terg R; Flamm S; Moreno-Otero R; Carrilho F; Schmidt W; Berg T; McGarrity T; Heathcote EJ; Gonçales F; Diago M; Craxi A; Silva M; Bedossa P; Mukhopadhyay P; Griffel L; Burroughs M; Brass C; Albrecht J;
    Gastroenterology; 2009 May; 136(5):1618-28.e2. PubMed ID: 19208349
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Ribavirin concentration in the later stages of 48 week pegylated interferon-alpha2b plus ribavirin therapy for chronic hepatitis C is useful for predicting virological response.
    Furusyo N; Murata M; Ogawa E; Toyoda K; Ihara T; Ikezaki H; Hayashi T; Koga T; Kainuma M; Hayashi J
    J Antimicrob Chemother; 2011 May; 66(5):1127-39. PubMed ID: 21393126
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Simeprevir with pegylated interferon alfa 2a plus ribavirin in treatment-naive patients with chronic hepatitis C virus genotype 1 infection (QUEST-1): a phase 3, randomised, double-blind, placebo-controlled trial.
    Jacobson IM; Dore GJ; Foster GR; Fried MW; Radu M; Rafalsky VV; Moroz L; Craxi A; Peeters M; Lenz O; Ouwerkerk-Mahadevan S; De La Rosa G; Kalmeijer R; Scott J; Sinha R; Beumont-Mauviel M
    Lancet; 2014 Aug; 384(9941):403-13. PubMed ID: 24907225
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Short duration treatment in genotype 1 chronic hepatitis C patients with rapid virologic response to pegylated interferon plus ribavirin.
    Bonardi R; Tabone M; Manca A; Pellicano R; Ciancio A; Rizzetto M
    Biomed Pharmacother; 2011 Jul; 65(4):303-6. PubMed ID: 21723079
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Hyperinsulinaemia reduces the 24-h virological response to PEG-interferon therapy in patients with chronic hepatitis C and insulin resistance.
    Bortoletto G; Scribano L; Realdon S; Marcolongo M; Mirandola S; Franceschini L; Bonisegna S; Noventa F; Plebani M; Martines D; Alberti A
    J Viral Hepat; 2010 Jul; 17(7):475-80. PubMed ID: 19878535
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Evaluation of prognostic factors for Peg Interferon alfa-2b plus ribavirin treatment on HCV infected patients in Pakistan.
    Aziz H; Gil ML; Waheed Y; Adeeb U; Raza A; Bilal I; Athar MA
    Infect Genet Evol; 2011 Apr; 11(3):640-5. PubMed ID: 21316487
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Peginterferon alfa-2b plus weight-based ribavirin for 24 weeks in patients with chronic hepatitis C virus genotype 1 with low viral load who achieve rapid viral response.
    Craxi A; Koutsounas S; Ogurtsov P; Chemello L; Maticic M; Torras J; Diago M; Tartaglione MT; Witthoeft T; Yu X; Faruqi R; Chaudhri E; Pedicone LD; Zuckerman E
    J Viral Hepat; 2012 Feb; 19(2):e120-5. PubMed ID: 22239509
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Response to pegylated interferon plus ribavirin in HIV-infected patients with chronic hepatitis C due to genotype 4.
    Martín-Carbonero L; Puoti M; García-Samaniego J; De Luca A; Losada E; Quinzan G; Bruno R; Mariño A; González M; Núñez M; Soriano V
    J Viral Hepat; 2008 Oct; 15(10):710-5. PubMed ID: 18637070
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Sustained HCV clearance by interferon-based therapy reduces hepatocellular carcinoma in hepatitis B and C dually-infected patients.
    Hung CH; Lu SN; Wang JH; Hu TH; Chen CH; Huang CM; Lee CM
    Antivir Ther; 2011; 16(7):959-68. PubMed ID: 22024511
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Steatosis is the predictor of relapse in HCV genotype 3- but not 2-infected patients treated with 12 weeks of pegylated interferon-α-2a plus ribavirin and RVR.
    Restivo L; Zampino R; Guerrera B; Ruggiero L; Adinolfi LE
    J Viral Hepat; 2012 May; 19(5):346-52. PubMed ID: 22497814
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.